Durvalumab is a drug that stimulates the immune system to fight lung cancer. Durvalumab is
FDA approved to treat lung cancer. Stereotactic body radiation therapy (SBRT) is a newer
radiation treatment that gives fewer, but higher doses of radiation than standard radiation.
With SBRT, radiation is focused toward the cancer and away from normal surrounding lung
tissue. It is possible that when cancer cells are damaged by SBRT Durvalumab may be more
effective in activating the immune system. SBRT is a standard FDA approved treatment for
early stage (stage 1) lung cancer and is investigational in patients such as yourself with
stage 3 lung cancer. The combination of Durvalumab and SBRT is investigational. This study
will investigate the effects, good and bad, of the combination of Durvalumab and SBRT.
Stage III Non-small-cell Lung Cancer,
Stage III Non-small-cell Lung Cancer
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.